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Linking altered central pain processing and
genetic polymorphism to drug efficacy in
chronic low back pain
Andreas Siegenthaler1, Jürg Schliessbach2*, Pascal H. Vuilleumier2, Peter Juni3, Hanns U. Zeilhofer4,
Lars Arendt-Nielsen5 and Michele Curatolo5,6
Abstract
Background: Inability to predict the therapeutic effect of a drug in individual pain patients prolongs the process
of drug and dose finding until satisfactory pharmacotherapy can be achieved. Many chronic pain conditions are
associated with hypersensitivity of the nervous system or impaired endogenous pain modulation. Pharmacotherapy
often aims at influencing these disturbed nociceptive processes. Its effect might therefore depend on the extent to
which they are altered. Quantitative sensory testing (QST) can evaluate various aspects of pain processing and
might therefore be able to predict the analgesic efficacy of a given drug. In the present study three drugs
commonly used in the pharmacological management of chronic low back pain are investigated. The primary
objective is to examine the ability of QST to predict pain reduction. As a secondary objective, the analgesic effects
of these drugs and their effect on QST are evaluated.
Methods/Design: In this randomized, double blinded, placebo controlled cross-over study, patients with chronic
low back pain are randomly assigned to imipramine, oxycodone or clobazam versus active placebo. QST is assessed
at baseline, 1 and 2 h after drug administration. Pain intensity, side effects and patients’ global impression of
change are assessed in intervals of 30 min up to two hours after drug intake. Baseline QST is used as explanatory
variable to predict drug effect. The change in QST over time is analyzed to describe the pharmacodynamic effects
of each drug on experimental pain modalities. Genetic polymorphisms are analyzed as co-variables.
Discussion: Pharmacotherapy is a mainstay in chronic pain treatment. Antidepressants, anticonvulsants and opioids
are frequently prescribed in a “trial and error” fashion, without knowledge however, which drug suits best which
patient. The present study addresses the important need to translate recent advances in pain research to clinical
practice. Assessing the predictive value of central hypersensitivity and endogenous pain modulation could allow for
the implementation of a mechanism-based treatment strategy in individual patients.
Trial registration: Clinicaltrials.gov, NCT01179828
Background
Drug therapy is an essential part of chronic pain treat-
ment. However, only a minor part of pain patients suffi-
ciently benefits from the available treatments or is able
to tolerate the drugs. One important limitation of drug
therapy is lack of instruments to predict their effect. For
this reason, patients are often prescribed medications on
a trial-and-error basis. Several attempts are typically
required until an appropriate treatment can be installed.
In clinical practice “classes” of drugs (e.g. antidepres-
sants) are given to “classes” of patients (e.g. neuropathic
pain patients). However, within those classes of patients,
very different pain mechanisms are likely to underlie the
pain condition in different individuals. Drugs that affect
part of these mechanisms will therefore probably not
work in all patients. Another reason for variability in drug
responses is genetic variation, leading to a spectrum of
different responses to analgesics, including lack of efficacy,
exaggerated response or even intolerable adverse effects.
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Quantitative sensory testing (QST) comprises methods
that assess alterations and reorganization of the nocicep-
tive system. Presence of an abnormal measurement in a
chronic pain patient could provide us with the informa-
tion that the underlying pain pathways might somehow
be altered [1]. An essential question is whether this infor-
mation can be linked to drug efficacy in a mechanism-
based treatment approach. QST has already been shown
to predict the efficacy of duloxetine in painful diabetic
neuropathy [2] and of pregabalin in chronic pancreatitis
[3]. For one of the most common chronic pain disorders,
namely chronic low back pain, such investigations have
not yet been reported.
Genetic variations such as polymorphisms of drug me-
tabolizing enzymes affect drug response as well. A fur-
ther important question is therefore whether assessing
genetic polymorphisms before initiating pharmacological
treatment can explain different drug effects and hence
help selecting the appropriate therapeutic strategy for
individual patients.
Objective
Three drugs are administered in three cohorts of patients
suffering from chronic low back pain: the tricyclic anti-
depressant imipramine, the opioid agonist oxycodone and
the GABAA-agonist clobazam.
The primary aim of this study is to investigate whether
quantitative sensory tests measured before drug admin-
istration can predict the analgesic efficacy of a single oral
dose of each of the three drugs.
The secondary aim is to further investigate the effect
of each drug on the intensity of chronic low back pain
and to analyze how quantitative sensory tests are influ-
enced by each drug over time. Genetic factors affecting
drug metabolism and pain sensitivity will be analyzed as
additional explanatory variables for drug efficacy.
Status
The study is currently running. Recruitment has been
completed, but no data have yet been published and no
paper has been submitted. Since several publications are
expected to result from this project, we present this
protocol as a future reference in order to improve the
readability of the resulting studies and to describe in
detail the methods, design and allocation processes that
are being used. The flow of patients through the study is
depicted in detail in the flowchart in Fig. 1.
Methods
Design
This randomized placebo-controlled trial in consecutive pa-
tients with chronic low back pain is carried out at the
University Department of Anesthesiology and Pain Therapy
of the Inselspital Bern, Switzerland. The study is approved
by the local ethics committee (KEK 213–09), registered
with clinicaltrials.gov (NCT01179828) and strictly
follows good clinical practice guidelines and the
Helsinki declaration.
Primarily, the data of each drug are analyzed separately,
resulting in three sub-studies. Patients will be randomly
assigned to one of them. These three sub-studies have the
same aims, use the same experimental procedures and stat-
istical analyses. The only difference among the three sub-
studies is the drug investigated. The inclusion of the three
sub-studies in the same protocol and the random allocation
of patients to the sub-studies may allow secondary explora-
tory analyses comparing the effects of the three drugs. The
active placebo tolterodine is used in order to control for a
possible placebo effect of the investigated drugs [4–6].
Patients
We test consecutive patients with chronic low back pain
referred to the Pain Division or recruited by advertising.
Chronic low back pain is defined as the presence of low
back pain on most days for the duration of three months
or longer [7, 8]. Any regular pain medication is stopped
one week prior to the first experiment. During the study
period, only acetaminophen and ibuprofen are allowed
as rescue medication, but they must as well be stopped
24 h before a testing session. Patients unable to stop
their analgesic regimen because of pain exacerbation are
not included in the study.
Exclusion criteria are:
– Age less than 18 or more than 80 years
– Pain intensity at rest < 3/10 on the numerical rating
scale (NRS) at the time of testing, whereby 0 = no
pain and 10 = worst pain imaginable
– Suspected radicular pain, as defined by leg pain
associated with an MRI finding of a herniated disc,
or foraminal stenosis with contact to a nerve root
– Signs or suspicion of neurological dysfunction at the
tested sites
– Pregnancy or breast feeding as assessed by
pregnancy test
– Ongoing treatment with an antidepressant, opioid or
benzodiazepine or intake of other centrally active
substances (including drug or alcohol abuse)
– Known allergy or pharmacological contraindications
to any of the tested substances
– Multi-site or widespread pain as well as systemic
inflammatory or rheumatological disease
– Major depression (Beck depression inventory short
form score >9)
Since all the patients are randomly assigned to one of
the 3 study groups, pharmacological contraindications
Siegenthaler et al. BMC Pharmacology and Toxicology  (2015) 16:23 Page 2 of 7
for all 3 substances have to be considered. Elevated eye
pressure, obstructive uropathy, severe heart disease
and documented QTc prolongation, documented or
suspected ischemic heart disease are special contrain-
dications for the use of imipramine. Severe pulmonary
disease with or without heart failure, hypoxemia,
neuromuscular disease (e.g. myasthenia gravis) and
neurologic disease are additional contraindications for
opioids and to a lesser extent for clobazam. History of
lack of effectiveness or known occurrence of intoler-
able side effects after intake of one of the study drugs
are exclusion criteria as well.
Drugs investigated
Imipramine
Antidepressant drugs have been used for many years to
treat chronic pain patients, especially suffering from
neuropathic pain, independent of a concomitant de-
pressive disorder. For classical tricyclic antidepressants,
the number-needed-to-treat (NNT) for chronic neuro-
pathic pain is approximately 3 for moderate pain relief
[9]. Antidepressants are also effective in musculoskel-
etal pain conditions [10–12], possibly because of their
effect on the endogenous modulating mechanisms in-
volving the monoaminergic system [12]. A single oral
Fig. 1 Presents the flow of participants through the study. From the initially included 90 patients, 34 decided to participate in a second session,
the remaining 56 declined further participation. Twenty-five of the 34 re-randomized patients wished to participate in the third session. This resulted in
an overall allocation of 50 patients to both the oxycodone and imipramine arm and 49 patients to the clobazam arm. NRS = numeric rating scale
(0 = no pain, 10 = worst pain imaginable)
Siegenthaler et al. BMC Pharmacology and Toxicology  (2015) 16:23 Page 3 of 7
dose of imipramine 100 mg was effective in studies using
experimental pain tests in healthy volunteers [13, 14].
Considering that our patient population would be older,
we choose a dose of 75 mg.
Oxycodone (immediate release)
Oxycodone is an opioid agonist largely used for different
chronic neuropathic, musculoskeletal and neoplastic
pain conditions. It may be effective in chronic musculo-
skeletal pain [15]. A single oral dose of oxycodone 15 mg
is administered in this study. This has been shown to effect-
ively modulate multimodal experimental pain in healthy
volunteers without causing major adverse effects [16].
Clobazam
Inflammatory and neuropathic conditions cause reduced
nociceptive control within the spinal cord via inhibition
of the GABAA-receptor [17], leading to pain facilitation.
Benzodiazepines produce antinociception in animal pain
models by acting on the GABAA-receptor [18] and are,
therefore, of potential interest in human pain manage-
ment as well. The benzodiazepine that is most com-
monly prescribed in pain treatment is clonazepam.
However, sedation strongly limits its clinical usefulness.
Clobazam is another GABAergic compound that causes
less sedation than clonazepam [19], making it a poten-
tially interesting drug in the clinical management of
pain. Studies on its efficacy in chronic pain are lacking.
A dose of 20 mg is chosen, corresponding to an equiva-
lent anticonvulsant dose of 0.5 mg clonazepam.
Active placebo: tolterodine
All of the evaluated drugs are likely to be associated with
minor central side effects, such as dizziness or sedation.
While these side effects are only transient and irrelevant
for the patient safety overall, they can potentially impair
blinding of patients and investigators. Therefore, an
active placebo has to be chosen that produces similar
central side effects, but has no analgesic effectiveness.
Tolterodine is an anticholinergic compound prescribed
in hyperactive bladder, which, as other anticholinergic
compounds, causes some sedation and dry mouth, but is
devoid of analgesic effects. The starting dose usually rec-
ommended in the Swiss Drug Compendium is 2 mg
twice a day, which can be decreased to 1 mg twice a day.
In order to minimize the likelihood of excessive side
effects, a dose of 1 mg is given in this study.
Concealment of allocation and blinding
Randomization is performed by the hospital pharmacy
in blocks of 6 based on computer generated random
numbers. Tablets are concealed in red colored gelatin
capsules (LGA, France) and packed into semi-opaque
flasks labelled with the patient and session number, lot
number and expiry date. All processes strictly follow
good manufacturing practice (GMP) guidelines. Both
investigators and patients are blinded as to the sequence
of application of the study drug and placebo. Patients
are allowed to participate in more than one drug arm if
they wish. These cases are announced prospectively to
the pharmacy, which ensures that the patient is not acci-
dentally allocated to the same sub-study in which he
already participated earlier. This procedure does not
negatively influence randomization or blinding. Patients
participating in more than one sub-study repeat the ac-
tive placebo session for each additional drug arm.
Mechanisms assessed
All three drugs may affect endogenous pain modulation
(i.e. endogenous mechanisms that attenuate or enhance
nociceptive processes) and hypersensitivity (i.e. increased
sensitivity to pain that is typically associated with
chronic pain states [20]). These disturbances will there-
fore be the primary predictive variables for drug efficacy.
Control of nociceptive processes by the endogenous in-
hibitory system is evaluated by conditioned pain modu-
lation (CPM) and generalized hypersensitivity is assessed
by pressure and electrical pain thresholds.
Genetic polymorphisms may either affect pain sensitivity
in general or the metabolism of the investigated drugs.
We therefore genotype the following cytochromes:
CYP2C19 (involved in imipramine and clobazam metabol-
ism), CYP2D6 (involved in imipramine and oxycodone
metabolism) and CYP3A4 (oxycodone and clobazam me-
tabolism) [21, 22]. The μ-opioid receptor variant A118G
(oxycodone binding site) is genotyped in the oxycodone
arm [23]. Polymorphisms of pain genes known to alter re-
sponses to experimental pain are determined in all pa-
tients: COMT (catechyl-o-methyltransferase [24]); GCH-1
(GTP-Cyclohydroxylase [25]) and the potassium channel
subunit KCNS1 [26]. Genotyping is performed using real-
time PCR and identification of specific variants by means
of melting curve analysis. A list of the specific polymor-
phisms that are analyzed can be found in table 1.
Quantitative sensory tests
During the experimental session, patients are positioned
in a comfortable supine position, with the upper body el-
evated by 30°, in a closed and quiet room. Before starting
the experiment, training sessions of the pain tests are
performed until the subjects are familiar with the testing
procedures. All QST measurements are performed on the
more painful body side. In case of bilateral or midline
pain, the side is randomly selected by drawing lots. All
QST measurements are performed at baseline and 1 and 2
h after drug administration. Triplicate measurements are
made for all tests except for conditioned pain modulation
and train-of-twenty stimulation (see below).
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Pressure pain thresholds
Pressure pain detection and tolerance thresholds (PPDT
and PPTT, respectively) are measured with an electronic
pressure algometer (Somedic AB, Horby, Sweden) [27]
applied at the center of the pulp of the 2nd toe. The
probe has a surface area of 1 cm2. The pressure is in-
creased from 0 at a rate of 30kPa/s to a maximum pres-
sure of 1000kPa. Pain detection threshold is defined as
the point at which the pressure sensation turns to pain.
Pain tolerance threshold is defined as the point at which
the subject feels pain as intolerable. The subjects are
instructed to press a button when these points are reached.
If the subjects do not press the button at a pressure of 1000
kPa, this value is considered as threshold.
Single and repeated electrical stimulation
Electrical single and repeated pain thresholds (ESPT and
ERPT, respectively) are performed using a computer-
controlled constant current stimulator (Digitimer Ltd,
England). Bursts of five 1 ms square wave impulses within
25 ms (perceived as one single stimulus) are delivered via
two Ag-AgCl electrodes placed distal to the lateral malle-
olus in the innervation area of the sural nerve. The
current intensity is increased from 1 mA in steps of 1 mA
until the sensation becomes painful (ESPT). For ERPT, the
stimuli are repeated five times at a frequency of 2 Hz.
Current intensity of all 5 stimuli are increased in steps of
1 mA until the last 2–3 stimuli are perceived as painful,
corresponding to the temporal summation threshold.
Heat and cold pain thresholds
Temperature pain thresholds are assessed using a peltier
thermode (TSA II, Medoc, Israel) with a probe surface
of 3x3 cm. Starting at 30.0 °C, the temperature is chan-
ged at a rate of 1 °C/s. Subjects will stop the measure-
ments by pressing a button when the warm sensation
turns to pain (heat pain detection threshold, HPDT) or
when it becomes intolerable (heat pain tolerance thresh-
old, HPTT), or when the cold sensation starts to be painful
(cold pain detection, CPDT). In any case, the measure-
ments will be stopped at 50.5 °C for HPTT or 0 °C for
CPDT, respectively. Measurements are made at the lateral
aspect of the lower leg (dermatome L5) and the radial sur-
face of the proximal forearm (dermatome C6).
Conditioned pain modulation (CPM)
This method explores the endogenous modulation of
nociceptive input. Under normal conditions, pain after
application of a test stimulus is attenuated by the applica-
tion of an additional “conditioning” stimulus to a remote
body region [28, 29]. The cold pressor test will be used as
the conditioning stimulus. Subjects will immerse their
contralateral hand into ice-saturated water (1.5 ± 1 °C)
until they rate the cold pain as 7/10 on the NRS. During
the baseline measurements, a single assessment of PPDT
is performed as test stimulus. An increase in PPDT com-
pared to the measurement before hand immersion is an
indication of CPM.
Electrical repeated stimuli are as well used as a test
stimulus for CPM. A train-of-five electrical stimulus at
an intensity of 1.2 times the ERPT is rated by the subject
on a 0–10 NRS before and during the cold pressor test.
A decrease in pain rating during the cold pressor test is
another indication of CPM. These assessments will be
performed at baseline as well as 1 and 2 h after drug
intake in order to study the influence of the drug on
endogenous pain modulation.
Electrical train-of-twenty stimulation
The arithmetical mean of three ERPT assessments at base-
line are used to deliver 20 identical stimuli over 10 s with
a frequency of 2 Hz. This stimulus intensity remains
constant over the two subsequent measurements 1 and 2
h after drug intake. Subjects rate the maximal and final
pain intensity during this stimulation on a 0–10 NRS. A
decrease in pain intensity in the subsequent measure-
ments would be indicative of an analgesic effect and a
Table 1 List of polymorphisms examined
KCNS1 rs734784
GCH-1 rs8007267
rs3783641
rs10483639
OPRM A118G rs1799971
COMT rs6269
rs4633
rs4818
rs4680
CYP3A 3A4*1b rs2740574
3A4 rs4646437
3A5*3 rs776746
CYP2D6 CYP2D6*6 rs5030655
CYP2D6*7 rs5030867
CYP2D6*8 rs5030865
CYP2D6*10 rs1065852
Cyp2D6*41 rs28371725
CYP2D6*3A rs35742686
CYP2D6*4 rs3892097
CYP2D6*5 Complete deletion of gene
CYP2D6*2 Duplication; more than one *2 variant
CYP2C19 CYP2C19*1 n/a
CYP2C19*2 rs4244285
CYP2C19*3 Rs4986893
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difference between maximal and final pain intensity dur-
ing the 20 stimulations is considered a feature of endogen-
ous pain modulation.
Pain intensity, side effects and global impression of change
The intensity of low back pain is rated by the patient on
a 0–10 NRS in both the sitting and supine position. The
occurrence of nausea, vomiting, sedation and dizziness
are also recorded on 0–10 NRS, whereby 0 = no side
effect at all and 10 = extreme occurrence of side effect.
Any other reported side effect will be recorded. The pa-
tients’ global impression of change scale (PGIC) consists
of a 7-point Likert scale ranging from 1 = “very much
improved” over 4 = “no change at all” to 7 = “very much
worse”. Pain intensity, side effects and PGIC will be
assessed in intervals of 30 min up to two hours after
drug intake.
Outcome parameters
For the primary objective, which is to predict analgesic
efficacy of each drug, pain intensity on a 0–10 NRS in
the supine position after 2 h is the primary outcome par-
ameter. Pain in the sitting position and PGIC will be
secondary outcome parameters. Baseline QST parame-
ters, genetic variants and side effects will be used as
explanatory (independent) variables.
For the secondary objective, which is to document the
analgesic effect of each drug, the primary outcome par-
ameter will again be the intensity of low back pain in the
supine position on a 0–10 NRS. All QST parameters will
be secondary outcome variables.
Descriptive variables
The following descriptive variables will be recorded: age,
gender, body mass index, pain intensity at time of test-
ing, average pain intensity in the last 24 h before testing
(0–10 NRS), duration of pain in months, history of sur-
gery due to painful condition (yes/no), pain-related life
interference as assessed by the Multidimensional Pain
Inventory (MPI) [30], Catastrophizing scale [31] and the
Beck Depression Inventory (BDI) short form [32].
Sample size considerations
Based on a correlation of pain scores across active and
placebo phase within a patient of 0.65, a prevalence of
treatment responders of 40 %, an average difference of
pain reduction measured with the NRS-scale between
the active drug and placebo of 2.5 in the treatment re-
sponders and 0 in “treatment non-responders”, 50 patients
per sub-study will be required to detect an interaction
between treatment effect and QST-status at a two-sided
alpha-level of 5 % with a power of 90 %.
Data analysis
Repetitive assessments of pain intensity (NRS, primary
endpoint) and Patients Global Impression of Change
Scale (secondary endpoint), recorded 30, 60, 90 and 120
min after intake of active treatment or placebo, will be
analyzed using a multilevel model adjusted for baseline
values, with random effects at the level of patients and
test phases (verum vs. placebo). Analyses will be strati-
fied according to QST-status and pharmacogenomic
characteristics. A formal test of interaction between
treatment, QST and pharmacogenomic status will be
performed. The primary and secondary endpoints, as
well as the primary and secondary predictive variables
are described above in page 17/18 and 11, respectively.
Data validation, query management and analysis will be
performed by CTU Bern. The data analyst will be
blinded as to the allocated interventions for primary
analyses. P-values are 2-sided. Analyses will be performed
in Stata 10 (Stata Corporation, College Station, Tex).
Discussion
Identifying the best drug in a given patient is a time con-
suming and frequently frustrating task for all the persons
involved. The growing knowledge about pain perception
and transmission has led to a new understanding of how
chronic pain might be maintained and offers several new
targets for therapeutic management. Such mechanism-
based treatment approaches are given high priority in
translational pain research. The combination of phenotyp-
ing disturbances in pain processing and genotyping pre-
disposition to pain and polymorphism in drug metabolism
may offer the perspective of a more specific treatment of
chronic pain. This may ultimately lead to a better selection
of the therapeutic strategy in individual patients, thereby
reducing the likelihood of ineffective treatment and
adverse effects.
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